What was the overall market valuation of the US intracranial hemorrhage-diagnosis-and-treatment market in 2024?

The overall market valuation was $241.65 Million in 2024. Read More

What is the projected market valuation for the US intracranial hemorrhage-diagnosis-and-treatment market by 2035?

The projected valuation for 2035 is $661.7 Million. Read More

Which companies are considered key players in the US intracranial hemorrhage-diagnosis-and-treatment market?

Key players include Medtronic, Johnson & Johnson, Stryker, Baxter International, Boston Scientific, Abbott Laboratories, Terumo Corporation, Nico Corporation, and Penumbra Inc. Read More

What were the market values for the Intracerebral Hemorrhage segment in 2024?

The market values for the Intracerebral Hemorrhage segment ranged from $60.0 Million to $170.0 Million in 2024. Read More

How did the Subarachnoid Bleeding segment perform in 2024?

The Subarachnoid Bleeding segment had market values between $50.0 Million and $140.0 Million in 2024. Read More

What is the market value range for Non-invasive devices in the US intracranial hemorrhage-diagnosis-and-treatment market?

The market value range for Non-invasive devices is projected between $161.65 Million and $441.7 Million. Read More

What were the market values for Diagnosis and Treatment in 2024?

The market values for Diagnosis and Treatment ranged from $80.0 Million to $220.0 Million in 2024. Read More

What is the expected growth trend for the Epidural Hematoma segment by 2035?

The Epidural Hematoma segment is expected to grow, with values projected between $30.0 Million and $80.0 Million. Read More

How does the market for Invasive devices compare to Non-invasive devices in terms of valuation?

Invasive devices had a market value range of $80.0 Million to $220.0 Million, while Non-invasive devices ranged from $161.65 Million to $441.7 Million. Read More

US Intracranial Hemorrhage Diagnosis and Treatment Market

Q: What is the expected CAGR for the US intracranial hemorrhage-diagnosis-and-treatment market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 9.59%. Read More

ID: MRFR/HC/11772-HCR

200 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Intracranial Hemorrhage Diagnosis and Treatment Market Research Report By Type (Intracerebral Hemorrhage, Subarachnoid Bleeding, Epidural Hematoma, Subdural Blood Hematoma), By Diagnosis (CT, MRI, Others), and By Treatment (Medication, Surgery) -Forecast to 2035

US Intracranial Hemorrhage Diagnosis and Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Pharmaceutical, BY Type (USD Million) | |
  1. 4.1.1 Intracerebral Hemorrhage | |
  2. 4.1.2 Subarachnoid Bleeding | |
  3. 4.1.3 Epidural Hematoma | |
  4. 4.1.4 Subdural Blood Hematoma | |
  5. 4.1.5 Postpartum hemorrhage | |
  6. 4.1.6 Pulmonary hemorrhage |
2. 4.2 Pharmaceutical, BY Devices (USD Million) | |
  1. 4.2.1 Invasive | |
  2. 4.2.2 Non-invasive |
3. 4.3 Pharmaceutical, BY Diagnosis and Treatment (USD Million) | |
  1. 4.3.1 Diagnosis | |
  2. 4.3.2 Treatment 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Medtronic (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Johnson & Johnson (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Stryker (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Baxter International (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Boston Scientific (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Abbott Laboratories (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Terumo Corporation (JP) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Nico Corporation (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Penumbra Inc. (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 US MARKET ANALYSIS BY TYPE |
6. 6.3 US MARKET ANALYSIS BY DEVICES |
7. 6.4 US MARKET ANALYSIS BY DIAGNOSIS AND TREATMENT |
8. 6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL |
9. 6.6 RESEARCH PROCESS OF MRFR |
10. 6.7 DRO ANALYSIS OF PHARMACEUTICAL |
11. 6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL |
12. 6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL |
13. 6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL |
14. 6.11 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE) |
15. 6.12 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million) |
16. 6.13 PHARMACEUTICAL, BY DEVICES, 2024 (% SHARE) |
17. 6.14 PHARMACEUTICAL, BY DEVICES, 2024 TO 2035 (USD Million) |
18. 6.15 PHARMACEUTICAL, BY DIAGNOSIS AND TREATMENT, 2024 (% SHARE) |
19. 6.16 PHARMACEUTICAL, BY DIAGNOSIS AND TREATMENT, 2024 TO 2035 (USD Million) |
20. 6.17 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
21. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
22. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY DEVICES, 2025-2035 (USD Million) | |
  3. 7.2.3 BY DIAGNOSIS AND TREATMENT, 2025-2035 (USD Million) |
23. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
24. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

Intracerebral Hemorrhage
Subarachnoid Bleeding
Epidural Hematoma
Subdural Blood Hematoma
Postpartum hemorrhage
Pulmonary hemorrhage

Pharmaceutical By Devices (USD Million, 2025-2035)

Invasive
Non-invasive

Pharmaceutical By Diagnosis and Treatment (USD Million, 2025-2035)

Diagnosis
Treatment

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓